NCT04214392View on ClinicalTrials.gov

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

June 9, 2026

Study Completion Date

June 9, 2026

Conditions
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent WHO Grade II GliomaRecurrent WHO Grade III Glioma
Interventions
BIOLOGICAL

Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)

Given via ICT delivery

BIOLOGICAL

Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)

Given via ICT/ICV dual delivery

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER